*  Adult Acute Lymphoblastic Leukemia: Remission Induction - UNM Comprehensive Cancer Center
Therapy is divided into two phases, remission induction and post-remission therapy. Remission induction chemotherapy is ... remission induction rate following remission induction treatment with Cerubidine® (daunorubicin), Oncovin, prednisone, and ... Following remission induction with hyper-CVAD the complete remission rate in older patients was 84% compared to 92% in younger ... Strategies to Improve Remission Induction. The development of intensive multi-agent chemotherapy induction regimens, ...
  http://cancer.unm.edu/2008/10/01/adult-acute-lymphoblastic-leukemia-remission-induction/
*  AB0465 Early remission induction and outcome in primary medium and small vessel vasculitis - retrospective review of ten years...
Rituximab has achieved remission in refractory vasculitis. Aggressive early induction therapy and sustained remission have ... AB0465 Early remission induction and outcome in primary medium and small vessel vasculitis - retrospective review of ten years ... AB0465 Early remission induction and outcome in primary medium and small vessel vasculitis - retrospective review of ten years ... treatment outcomes and to assess the impact of early remission induction therapy. ...
  http://ard.bmj.com/content/72/Suppl_3/A930.3
*  Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis - Tabular View - ClinicalTrials.gov
Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis. The safety and scientific validity of ... Prednisolone for Induction of Remission in Auto-immune Hepatitis. Brief Summary Untreated Autoimmune hepatitis (AIH) is a ... Alternative options for induction of remission are limited. There are reports of successful salvage therapy with Cyclosporine-A ... The investigators aim to assess the efficacy and tolerability of CsA directly to the CS for induction of remission in treatment ...
  https://clinicaltrials.gov/ct2/show/record/NCT01170351
*  5-ASA suppositories, enemas or foam for induction of remission in ulcerative colitis | Cochrane
5-ASA suppositories, enemas or foam for induction of remission in ulcerative colitis. Ulcerative colitis (UC) is a chronic ... Cyclosporine A for induction of remission in severe ulcerative colitis. *Methotrexate for treatment of chronic active ... Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2010, ... endoscopic remission 5.31 (7 trials, 95% CI 3.15 to 8.92; P , 0.00001), and histologic remission 6.28 (5 trials, 95% CI 2.74 to ...
  http://www.cochrane.org/CD004115/IBD_5-asa-suppositories-enemas-or-foam-for-induction-of-remission-in-ulcerative-colitis
*  Traditional Chinese medicinal herbs for induction of remission in advanced or late gastric cancer | Cochrane
Traditional Chinese medicinal herbs for induction of remission in advanced or late gastric cancer. Gastric cancer, one of the ... Yang J, Zhu L, Wu Z, Wang Y. Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Cochrane ... Although some chemotherapies or bio-therapies have made progress in the remission of this disease, the mortality from gastric ... To assess the effectiveness of Chinese medicinal herbs in the short-term remission of advanced or late gastric cancer. ...
  http://www.cochrane.org/CD005096/UPPERGI_traditional-chinese-medicinal-herbs-for-induction-of-remission-in-advanced-or-late-gastric-cancer
*  Chinese herbal medicines for induction of remission in advanced or late gastric cancer - The Cochrane Library - Yang - Wiley...
Yang J, Zhu L, Wu Z, Wang Y. Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Cochrane ... Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Tao Gan, Zongying Wu, Ling Tian and ... Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Tao Gan, Zongying Wu, Ling Tian and ... Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Jinlin Yang, Linlin Zhu, Zongying Wu ...
  http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005096.pub4/otherversions
*  Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease - Full Text View -...
Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease. The safety and scientific validity ... A Randomized, Single Blinded, Controlled, Multi Center Phase 4 Study for Induction of Remission in Active Pediatric Crohn's ... Background: Recent reviews and guidelines no longer recommend antibiotic therapy for induction of remission in Crohn's disease ... Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric ...
  https://clinicaltrials.gov/ct2/show/NCT01596894?recr=Open&cond=%22Crohn+Disease%22&rank=19
*  Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells for the Induction of Remission in Ulcerative Colitis - Full Text View ...
Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells for the Induction of Remission in Ulcerative Colitis (ALOASCU). The ... Remission will be considered if reaches 0 points and response if the score diminishes. Endoscopy will be performed at 0 and 8 ... Remission will be considered if it descends below 11, and response if it diminishes at least 30%. Modified Truelove-Witts score ... on Induction to Remission in Ulcerative Colitis. ... to evaluate the efficacy of the treatment to induce remission ...
  https://clinicaltrials.gov/ct2/show/NCT01914887?recr=Open&cond=%22Colitis%2C+Ulcerative%22&rank=19
*  BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of...
Induction of clinical remission [ Time Frame: 24 weeks ]. Clinical remission includes the ability to taper corticosteroids. ... safety and tolerability of blisibimod when taken with methotrexate in the induction of remission in ANCA-Associated Small ... and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small ... and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small ...
  https://clinicaltrials.gov/ct2/show/NCT01598857?recr=Open&cond=%22Granulomatosis+with+Polyangiitis%22&rank=6
*  SP0189 Induction of Remission by Low-Dose IL-2-Therapy in One SLE Patient with Increased Disease Activity Refractory to...
SP0189 Induction of Remission by Low-Dose IL-2-Therapy in One SLE Patient with Increased Disease Activity Refractory to ... SP0189 Induction of Remission by Low-Dose IL-2-Therapy in One SLE Patient with Increased Disease Activity Refractory to ...
  http://ard.bmj.com/content/73/Suppl_2/50.1
*  Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease - Full...
Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease. This study has ... To induce clinical remission and/or clinical response following 8 weeks of treatment [ Time Frame: 8 weeks ]. ... The purpose of this study is to evaluate if Leukine can induce clinical response or remission in patients with Crohn's disease. ... Randomized, Double-Blind, Placebo-Controlled, Phase 3 Induction Study to Assess the Efficacy and Safety of 6µg Sargramostim ( ...
  https://clinicaltrials.gov/ct2/show/NCT00295165
*  Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis, Digestive Diseases and...
"Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis, Digestive Diseases and ... Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis. Fernández-Blanco, J.; ... Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative... Fernández-Blanco, J.; ... Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis. ...
  https://www.deepdyve.com/lp/springer_journal/adalimumab-for-induction-of-histological-remission-in-moderately-to-4Brd5Ioz2J
*  Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease - Mayo...
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease. * Print ... Participants who complete the study, or do not meet protocol response or remission criteria at Week 10 will have the option to ... The primary objectives of this study are to evaluate the safety and efficacy of filgotinib during induction and maintenance ...
  http://www.mayo.edu/research/clinical-trials/cls-20307291
*  Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease - Full...
Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease. The safety ... Number of Participants in Clinical Remission at Treatment Week 20. Clinical Remission Defined as Harvey Bradshaw Index (HBI) ... Clinical remission = HBI less than 5. Highest total score at Baseline was 47. Missing data were imputed using non-responder ... Study of the Fully Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in ...
  https://clinicaltrials.gov/show/NCT00409617
*  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic...
Proportion of subjects who achieve remission at Week 52 [ Time Frame: Week 52 ]. Remission to be determined at Week 52 ... Active Comparator: Induction Period ABT-494 Low/Medium Dose Induction Period ABT-494 Low/Medium Dose orally dosed twice a day ... Active Comparator: Induction Period ABT-494 Twice Daily Medium/High Dose Induction Period ABT-494 Twice Daily Medium/High Dose ... Active Comparator: Induction Period ABT-494 Once Daily Medium/High Dose Induction Period ABT-494 Once Daily Medium/High Dose ...
  https://www.clinicaltrials.gov/ct2/show/NCT02365649?term=m13-740&rank=1
*  Interferon-α for Induction and Maintenance of Remission in Eosinophilic Granulomatosis with Polyangiitis: A Single-center...
Primary endpoints were remission induction, occurrence of relapses, prednisolone (PSL) dosage at time of remission, and adverse ... Interferon-α for Induction and Maintenance of Remission in Eosinophilic Granulomatosis with Polyangiitis: A Single-center ... Interferon-α for Induction and Maintenance of Remission in Eosinophilic Granulomatosis with Polyangiitis: A Single-center ... Interferon-α for Induction and Maintenance of Remission in Eosinophilic Granulomatosis with Polyangiitis: A Single-center ...
  http://www.jrheum.org/content/44/6/806
*  Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic...
The presence of a shared epitope was not related to the induction of remission. CONCLUSION The delay of a few months from the ... RESULTS The delay to therapy (cut point of 4 months) was the only significant predictor for remission in patients treated using ... The frequency of achieving remission in the combination-DMARD group after 2 years was similar in patients with short (0-4 ... on the prediction of disease remission after 2 years in patients with early rheumatoid arthritis (RA). METHODS In the FIN-RACo ...
  https://www.semanticscholar.org/paper/Delay-to-institution-of-therapy-and-induction-of-or-M%C3%B6tt%C3%B6nen-Hannonen/c87169e678eacce7c5704701c644de90c290f039
*  229 Mycophenolate mofetil for induction of remission in lupus enteritis | Lupus Science & Medicine
Conclusions Mycophenolate mofetil (MMF) appears promising as an agent of remission induction and maintenance in patients with ... their in vitro expression.The aim of study was to determine the efficacy of Mycophenolate mofetil in the induction of remission ... Subsequently, Mycophenolate mofetil 1000 mg twice a day was added in the regimen for remission. Only 1 patient developed ... All patients received induction with high dose pulse methylprednisone 1000 mg IV for three days followed by prednisone at a ...
  http://lupus.bmj.com/content/4/Suppl_1/A105.2
*  Acute Lymphoblastic Leukemia Treatment | OSUCCC - James
Remission Induction. The first treatment phase, is designed to destroy leukemia cells (called blasts) and put the cancer into ... Post-Remission Therapy or Remission Continuation Therapy Is the second phase, and this is designed to kill any remaining ... remission. This treatment usually begins with chemotherapy. After the patient is in remission, a second phase of therapy begins ...
  https://cancer.osu.edu/cancer-specialties/cancer-care-and-treatment/acute-lymphoblastic-leukemia/treatment
*  A Multicenter, Phase 2 Study of Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia in Complete Remission...
... who are in complete remission following initial chemotherapy, live ... Phase 2 Study of Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia in Complete Remission After Induction ... Phase 2 Study of Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia in Complete Remission After Induction ...
  http://adisinsight.springer.com/trials/700014243?error=cookies_not_supported&code=d997c051-d042-4146-b663-2eb69681eeb4
*  Talk: Rituximab Versus Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitis: A Randomized Controlled Trial...
RTX is not inferior to CYC for the induction of remission in severe AAV. These results provide strong support for the use of ... Combined use of cyclophosphamide (CYC) and glucocorticoids (GCS) has been the standard of care for remission induction for ANCA ... 550 - Rituximab Versus Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitis: A Randomized Controlled Trial ... for inducing remission in severe AAV. Once remission was achieved, CYC was replaced by azathioprine between months 3-6. All ...
  https://acr.confex.com/acr/2009/webprogram/Paper11655.html
*  An MRI-guided Treatment Strategy to Prevent Disease Progression in Patients With Rheumatoid Arthritis - Full Text View -...
Remission Induction. Synovitis/immunology. Synovitis/pathology. Wrist Joint/pathology. Wrist Joint/physiopathology. ... ACR/EULAR 2011 remission [ Time Frame: 24 month ]. ACR/EULAR 2011 remission at 12 and 24 months ... DAS28 remission (,2.6) [ Time Frame: 24 month ]. *No radiographic progression (assessed by the Sharp/vdHeijde method). [ Time ... DAS28 remission (,2.6) at 12 months [ Time Frame: 24 months ]. *biomarker analyses [ Time Frame: 24 month ]. ...
  https://clinicaltrials.gov/ct2/show/NCT01656278?recr=Open&cond=%22Connective+Tissue+Diseases%22&rank=6
*  https://www.cancer.gov/types/leukemia/patient/child-all-treatment-pdq
When children are in remission after remission induction therapy, a stem cell transplant using stem cells from a donor may be ... When children are not in remission after remission induction therapy, further treatment is usually the same treatment given to ... Remission induction: This is the first phase of treatment. The goal is to kill the leukemia cells in the blood and bone marrow ... The treatment of infants with ALL during the remission induction, consolidation /intensification, and maintenance phases always ...
  https://www.cancer.gov/types/leukemia/patient/child-all-treatment-pdq
*  Search of: adult acute myelomonocytic leukemia | 'Acute monoblastic leukemia' - List Results - ClinicalTrials.gov
Remission Induction Response. *Participants Experiencing a Dose-limiting Toxicity (DLT) of Bortezomib When Administered in ... Complete remission rate (complete remission [CR] or incomplete remission [CRi]). *Occurrence of serious infections (grade 4) ... Response rate (complete remission [CR], CR with incomplete blood count recovery [CRi], partial remission [PR] or stable disease ... Median duration of remission. 0. All. 18 Years and older (Adult, Senior). NCT01835288. HEMAML0023. NCI-2013-00767. 26938. May ...
  https://clinicaltrials.gov/ct2/results?term=adult+acute+myelomonocytic+leukemia&cond=%22Acute+monoblastic+leukemia%22
*  High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus.
... for identifying patients who will have a remission. METHODS: We studied 100 SLE patients (85 females, ... Remission Induction. Severity of Illness Index. From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine ... They remained in remission for a mean of 55 months. There were no statistical differences in SLEDAI values and the initial ... METHODS: We studied 100 SLE patients (85 females, 15 males) and identified all patients who had remission (defined as at least ...
  http://www.biomedsearch.com/nih/High-disease-activity-at-baseline/10501419.html